Share Price:

APNASPENAspen Pharmacare Hldgs23671136 (0.58%)

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform to be released on 4 March 2024.

Production

Team Overview

Aspen has 23 manufacturing facilities across 15 sites. One of our strategic thrusts is our manufacturing capability, and the sites we have in the group are not only known for quality and dependability but also are widely accredited, holding international approval from some of the most stringent global regulatory agencies. Our manufacturing capabilities spans a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and APIs. We have 7 API and 16 FDF manufacturing facilities worldwide. Our sites provide quality products whilst allowing for improved competitiveness and sustainability and they are pivotal to support our strategic manufacturing capacity requirements, to enable an affordable and secure supply of medicines and vaccines to markets across the world.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Etiam id nisl in urna euismod pellentesque vitae vitae mauris. Suspendisse faucibus ex sed convallis dignissim.

Name, Group Marketing Head

Working At Aspen

We believe that doing business in a sustainable and responsible manner is integral to our purpose, our values and our philosophy “Healthcare. We Care”.


Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business.

 

Our sustainability commitments are integrated into the Group’s strategic objectives and underpin the way we do business.

Innovation

We constantly search for better ways of doing things

Excellence

We strive to be the best we can be to deliver the highest standards

Commitment

We go the extra mile, seeking to exceed expectations

Teamwork

We optimise our performance by pulling together

Integrity

Our integrity is not negotiable

Closed Period

Aspen is in a closed period from 1 January until the publication of our interim results on the JSE SENS platform scheduled to be released on 1 March 2023.

The live presentation will take place in Cape Town at 08h30 on 2 March 2023.